Compare · MDXG vs NVS
MDXG vs NVS
Side-by-side comparison of MiMedx Group Inc (MDXG) and Novartis AG (NVS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDXG and NVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS is the larger of the two at $293.40B, about 458.1x MDXG ($640.5M).
- Over the past year, MDXG is down 32.8% and NVS is up 34.6% - NVS leads by 67.4 points.
- MDXG has been more active in the news (2 items in the past 4 weeks vs 1 for NVS).
- NVS has more recent analyst coverage (25 ratings vs 7 for MDXG).
- Company
- MiMedx Group Inc
- Novartis AG
- Price
- $4.31-2.82%
- $153.72+0.64%
- Market cap
- $640.5M
- $293.40B
- 1M return
- +16.80%
- +1.89%
- 1Y return
- -32.76%
- +34.60%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 2
- 1
- Recent ratings
- 7
- 25
MiMedx Group Inc
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, pressure ulcers, and burns; AmnioFix, a semi-permeable protective barrier membrane product for the treatment of wounds related to surgical procedures; EpiCord and AmnioCord that are dehydrated human umbilical cord allografts intended for homologous applications; and AmnioFill that consists of particles of connective tissue matrix derived from placental disc and placental membranes. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. is headquartered in Marietta, Georgia.
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Latest MDXG
- Chief Financial Officer Doug Rice covered exercise/tax liability with 12,749 shares, decreasing direct ownership by 3% to 399,566 units (SEC Form 4)
- Chief Commercial Officer Maersk-Moller Kimberly covered exercise/tax liability with 19,820 shares, decreasing direct ownership by 6% to 309,630 units (SEC Form 4) (withholding tax)
- MiMedx Group Inc filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders
- The Quiet Revolution in Regenerative Medicine: From Replacing Tissue to Rebuilding It
- Director Bierman James L was granted 50,913 shares, increasing direct ownership by 24% to 263,684 units (SEC Form 4)
- Director Puhy Dorothy E was granted 50,913 shares, increasing direct ownership by 88% to 108,510 units (SEC Form 4)
- Director Newton Todd was granted 50,913 shares, increasing direct ownership by 12% to 463,684 units (SEC Form 4)
- Director Hawkins William A was granted 50,913 shares, increasing direct ownership by 25% to 254,931 units (SEC Form 4)
- Director Olson Tiffany was granted 50,913 shares, increasing direct ownership by 88% to 108,510 units (SEC Form 4)
- A Fresh FDA Catalyst Is Putting Regenerative Wound Care in Focus
Latest NVS
- The Quest to Repair What Multiple Sclerosis Takes Away
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- Novartis AG upgraded by Argus with a new price target
- Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
- SEC Form S-8 filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form IRANNOTICE filed by Novartis AG